Abstract 1198: MatchMiner: An open-source computational platform that accelerates patient enrollment on to precision medicine trials
Authors: Harry Klein, Tali Mazor, Priti Kumari, James Lindsay, Andrea Ovalle, Ethan Siegel, Pavel Trukhanov, Joyce Yu, Michael Hassett, Ethan Cerami
Journal: Cancer Research (2021)

Abstract With the advent of next generation sequencing in cancer care, patients' tumors can be genomically profiled and specific genetic alterations can be targeted with precision medicine drugs. However, the abundance of patient sequencing data coupled with complex clinical trial eligibility has made it challenging to match patients to precision medicine trials. To facilitate interpretation of complex tumor sequencing data and clinical trial genomic eligibility criteria, we developed MatchMiner, an open-source platform to computationally match cancer patients to precision medicine clinical trials. MatchMiner supports two distinct workflows: (1) patient-centric mode, in which an oncologist can find clinical trial matches for a specific patient, and (2) trial-centric mode, in which a clinical trial investigator can identify and recruit patients for a specific trial. In MatchMiner at DFCI, there are currently 330+ precision medicine trials and genomic and genomic and clinical data from 39,000+ patients. Although MatchMiner has been operational at Dana-Farber Cancer Institute since early 2017, its impact on patient care has not yet been extensively studied. In this study, we analyzed temporal trends of 170 MatchMiner-driven trial enrollments. We compared these 170 MatchMiner-driven trial enrollments to non-MatchMiner-driven trial enrollments to determine how MatchMiner has impacted patient enrollments. To compare MatchMiner-driven trial enrollments to non-MatchMiner-driven enrollments, we limited the non-MatchMiner group by choosing patients who enrolled on the same trials. We also ensured that all patients in both enrollment groups had a genomic report present in MatchMiner before their consent date. We then analyzed temporal trends between genomic report dates, patient consent and on-study dates, and patient views in MatchMiner. MatchMiner-driven enrollments had a significant decrease in time from genomic report date to consent date compared to non-MatchMiner-driven enrollments. Thus, clinical use of MatchMiner decreased time to enroll in a precision medicine study, and suggests that use of precision medicine trial matching tools such as MatchMiner are important for the future of patient care. The MatchMiner open-source software package is available through GitHub (https://github.com/dfci/matchminer). We are committed to supporting MatchMiner as an open-source software; to our knowledge, at least five cancer centers are implementing MatchMiner. Citation Format: Harry Klein, Tali Mazor, Priti Kumari, James Lindsay, Andrea Ovalle, Ethan Siegel, Pavel Trukhanov, Joyce Yu, Michael Hassett, Ethan Cerami. MatchMiner: An open-source computational platform that accelerates patient enrollment on to precision medicine trials [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1198.